← back to database
Cure Ventures
HQ · Massachusetts
De novo life-science and biotechnology company formation around curative therapeutics. Seed model funds scientific de-risking and Cure embeds operators; invests in genetically validated therapeutic opportunities and co-leads later Series A/B rounds.
Stage focus
Lead / follow
Specialization
Generalist / Specialist
Specialist
Latest fund size
$350M — Cure Ventures Fund I, L.P.
Latest fund vintage
2023
Investing team
- William Amsbaugh, M.S.CTO and Partner
- Milenko Cicmil, Ph.D.Venture Partner
- David Fallace, J.D. / M.B.A.Managing Partner
- Jeno Gyuris, Ph.D.Partner
- May Han, Ph.D.Partner
- Jeffrey M. Jonas, M.D.Partner
- Kayarash Karimian, Ph.D.Senior Associate
- Drew King, CPA / M.S.A.CFO and Partner
- Virginia Lyle King, Ph.D.Senior Associate
- Richard J. Lim, M.B.A.Managing Partner
- Weihan Liu, Ph.D.Associate
- Kenzie MacIsaac, Ph.D.Partner
- Annie Mitsak, Ph.D.Partner
- Albert J. Robichaud, Ph.D.Partner
- Sophie Robinson, Ph.D.Senior Associate
- Lou Tartaglia, Ph.D.Managing Partner
How to reach them
Notable investments
April 21, 2026: Tortugas Neuroscience launched with $106M across Seed and Series A; issuer calls Cure Ventures the founding investor and confirms it led Seed and co-led Series A.
Sources
curevc.com/about-us ↗curevc.com/people ↗curevc.com/contact-us ↗curevc.com/cure-ventures-launches-with-close-of-inaugural-350-million-dollar-fund ↗tortugasneuro.com/tortugas-neuroscience-launches-to-advance-clinical-stage-pipeline-targeting-new-and-major-neurology-and-neuropsychiatric-disorders ↗curevc.com ↗